Thyroid Cancer Epidemic: A Peril or an Alarm?

Zahra Nozhat; Mehdi Hedayati; Feridoun Azizi

doi:10.5812/ijem.28491

Thyroid Cancer Epidemic: A Peril or an Alarm?

authors:

Zahra Nozhat ¹ , Mehdi Hedayati ¹ , avatar Feridoun Azizi ^{2
, *}

1 Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

2 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

International Journal of Endocrinology and Metabolism: Vol.13, issue 4; e28491

published online: October 10, 2015

article type: Letter

received: March 7, 2015

revised: June 9, 2015

accepted: July 8, 2015

DOI: https://doi.org/10.5812/ijem.28491

how to cite: Nozhat Z, Hedayati M, Azizi F. Thyroid Cancer Epidemic: A Peril or an Alarm?. Int J Endocrinol Metab. 2015;13(4):e28491. https://doi.org/10.5812/ijem.28491.

Keywords

Epidemic Cancer Queensland

Footnote

Authors’ Contributions:Study concept and design: Mehdi Hedayati. Acquisition of the data: Mehdi Hedayati and Zahra Nozhat. Analysis and interpretation of the data: Mehdi Hedayati, Zahra Nozhat, and Feridoun Azizi. Drafting of the manuscript: Mehdi Hedayati and Zahra Nozhat. Critical revision of the manuscript for important intellectual content: Mehdi Hedayati, Zahra Nozhat, and Feridoun Azizi. Statistical analysis: there is no statistical analysis. Administrative, technical, and material support: these items are not related to our study. Study supervision: Mehdi Hedayati.

References

1.
Barzon L, Boscaro M, Pacenti M, Taccaliti A, Palu G. Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. Int J Cancer. 2004;110(6):914-20. [PubMed ID: 15170676]. https://doi.org/10.1002/ijc.20182.
2.
Wartofsky L, Nostrand V. Thyroid cancer, a comprehensive guide to clinical management. Washington: Washington Hospital Center; 2006.
3.
Solomon B, Rischin D. Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer. J Clin Oncol. 2012;30(2):119-21. [PubMed ID: 22025155]. https://doi.org/10.1200/JCO.2011.37.8638.
4.
Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia. 2006;61(5):564-9. [PubMed ID: 17623957].
5.
Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, Rezghi Barez S, Hoghooghi Rad L, Azizi F. Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma. J Thyroid Res. 2011;2011:264248. [PubMed ID: 21765987]. https://doi.org/10.4061/2011/264248.
6.
Majidi M, Haghpanah V, Hedayati M, Khashayar P, Mohajeri-Tehrani MR, Larijani B. A family presenting with multiple endocrine neoplasia type 2B: A case report. J Med Case Rep. 2011;5:587. [PubMed ID: 22185228]. https://doi.org/10.1186/1752-1947-5-587.
7.
Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N Engl J Med. 2014;371(19):1765-7. [PubMed ID: 25372084]. https://doi.org/10.1056/NEJMp1409841.
8.
Pandeya N, McLeod DS, Balasubramaniam K, Baade PD, Youl PH, Bain CJ, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis? Clin Endocrinol (Oxf). 2015. [PubMed ID: 25597380]. https://doi.org/10.1111/cen.12724.

comments